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Abstract
Preclinical efforts to discover and develop new drugs and vaccines for tuberculosis are hampered by the reliance on colony-
forming unit (CFU) counts as primary outcomes for in vivo efficacy studies and the slow growth of Mycobacterium
tuberculosis. The utility of bioluminescent M. tuberculosis reporter strains for real-time in vitro and ex vivo assessment of drug
and vaccine activity has been demonstrated but a simple, non-invasive, real-time surrogate marker to replace CFU counts
for real-time evaluation of drug and vaccine efficacy in vivo has not been described. We describe the development of a fully
virulent and stable autoluminescent strain of M. tuberculosis and proof-of-concept experiments demonstrating its utility for
in vivo bioluminescence imaging to assess the efficacy of new drugs and vaccines for tuberculosis in a mouse model.
Relative light unit (RLU) counts paralleled CFU counts during the active phase of bacterial growth, with a lower limit of
detection of approximately 10
6 CFU in live, anesthetized mice. Experiments distinguishing active from inactive anti-
tuberculosis drugs and bacteriostatic drug effects from bactericidal effects were completed in less than 5 days. The ability of
a recombinant BCG vaccine to limit bacterial growth was demonstrated within 3 weeks. Use of this autoluminescent
reporter strain has the potential to drastically reduce the time, effort, animals and costs consumed in the evaluation of drug
activity in vitro and the in vivo assessment of drug and vaccine efficacy.
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Introduction
New tools are needed to enable development of more effective
preventive and therapeutic measures to control tuberculosis (TB),
which causes approximately9 million new cases and2 million deaths
annually. More potent chemotherapeutic agents could shorten the
treatment of active and latent TB infections, including those caused
by multidrug-resistant strains. More effective vaccines could prevent
infection or development of active TB. Efforts to discover and
develop drugs and vaccinesfor TB are hampered by the slow growth
ofMycobacteriumtuberculosis,whichrequires3–4weeksofincubationto
formcolonies onsolid media. Relianceon the conventional endpoint
of organ CFU counts is also costly in terms of the numbers of mice,
BSL-3 laboratory space and other resources needed to obtain and
cultivate animal tissues at each desired time point. A reliable non-
invasive, real-time method of quantifying viable M. tuberculosis in vitro
and in live animals could dramatically increase throughput and
accelerate the pace of discovery and development of new preventive
and therapeutic agents.
Light production by various luciferase enzymes has been used as
a real-time biomarker of bacterial viability for high-throughput
screening of antibiotics and drug susceptibility testing against
mycobacteria [1,2,3,4,5,6]. The bacterial luciferases encoded by
luxAB catalyze the oxidation of reduced flavin mononucleotide using
a long-chain fatty aldehyde substrate, producing H2O and light
(,490 nm wavelength) in the process. Other genes of the lux operon
(luxCDE) encode enzymes for the synthesis of the aldehyde substrate
[7] . Bioluminescence produced by a strain of Mycobacterium smegmatis
expressing luxAB from Vibrio harveyi was 2 orders of magnitude greater
than that produced by a comparable strain expressing firefly
luciferase [8]. Mycobacterial reporter strains expressing luxAB have
been used to screen antibiotics and biocides in vitro [9] and to
demonstrate proof-of-concept for evaluation of drug [3] and vaccine
efficacy [8] in mice, but these constructs required the addition of
exogenous substrate. Recently, Andreu et al [ 1 ]r e p o r t e do nt h e i r
efforts to optimize the expression of the entire luxCDABE operon in
mycobacteria, which culminated in non-invasive, real-time imaging
of M. smegmatis in the lungs of mice without the need for exogenous
substrate. However, effortstocreate a stable autoluminescentstrainof
M. tuberculosis that could be visualized in vivo were unsuccessful.
Here, we report the successful engineering of M. tuberculosis to
express the native luxCDABE operon from Photorhabdus luminescens
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29774and demonstrate proof-of-concept for rapid, serial, non-invasive,
real-time evaluation of anti-tuberculosis drug and vaccine efficacy
in vivo. The utility of such bioluminescent strains for high-
throughput screening of anti-tuberculosis activity in vitro is also
demonstrated.
Results
Selection of a stable and virulent autoluminescent strain
of M. tuberculosis H37Rv (AlRv)
The natural luxCDABE operon was cloned into four different
expression vectors under control of the constitutive hsp60 promoter
[10]. Although E. coli transformants containing each of three different
integrative plasmids and the extra-chromosome vector pTYOEH
were obtained, no M. tuberculosis clones with pTYOEH were obtained,
which is consistent with a recent report [1] that stable luminescent
mycobacterial clones could not be obtained using episomal vectors.
Transformants containing pTYOK and pTYZOK2 exhibited strong
luminescence, visible to the naked eye. The one containing pOAIK2
produced much weaker light. Clones containing pTYZOK1 or
pOAIK1 didnot produce lightabovebackgroundlevels,implying that
the orientation of the luxCDABE operon is important and that greater
expression of luxAB with additional copies does not increase light
production. The strain containing pTYOK was selected for further
study because it did not contain luxAB in addition to the luxCDABE
operon. This autoluminescent H37Rv (AlRv) strain grew as well as the
parent strain (WtRv), both in vitro (Figure 1A) and after high- and low-
dose aerosol infection of mice (Figure 1, B&C). High-dose infection
with either strain resulted in 100% mortality between 21 and 23 days
post-infection.
Correlation of luminescence and colony-forming unit
(CFU) counts in vitro and in vivo
During logarithmic growth of the AlRv strain in vitro (Figure 1A),
relative light unit (RLU) counts paralleled CFU counts. In
stationary phase, the RLU/CFU ratio declined steadily, presum-
ably due to reduced availability of the FMNH2 substrate, as
previouslydescribed[1].SimilarcorrespondencebetweenRLUand
CFU counts during logarithmic growth was observed in lung
homogenates after aerosol infection (Figure 1, B&C) (r
2=0.995 for
Figure 1. Growth comparison of WtRv and AlRv on the basis of RLU and CFU counts. In vitro (A), in lung homogenates from BALB/c mice
after high-dose aerosol infections (implanting 4.0560.11 and 4.4460.05 log10 CFU, respectively) (B) or low-dose infections (implanting 2.1560.08 and
2.7860.07 log10 CFU, respectively) (C), and in live, anesthetized mice after high dose infection (D).
doi:10.1371/journal.pone.0029774.g001
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2=0.978 for low-dose infection). As opposed
to the in vitro situation, however, the RLU/CFU ratio remained
similar in lung homogenates from mice receiving low-dose infection
even after CFU counts peaked with the onset of acquired immunity.
RLU counts in lung homogenates were at least 2 log10 greater than
background RLU values within 8 days of high-dose infection and
within 15 days of low-dose infection, providing an ample window
for the assessment of bactericidal and bacteriostatic properties of
antimicrobials. Most importantly, however, RLU could be detected
and serially monitored in real-time in live, anesthetized mice by the
second week after high-dose infection with AlRv (Figure 1D). RLU
countsinthesemice peaked at2.5log10RLUabovethe background
level before the animals succumbed to infection. In live low-dose-
infected mice, RLU counts only exceeded the background value for
a short window of time, when the CFU counts exceeded 6 log10
during weeks 3 to 6 post-infection (data not shown). Beyond that
point, RLU counts did not exceed the background value despite
stable CFU counts in the lungs just below 7 log10.
Serial, real-time monitoring of anti-tuberculosis drug
activity in vitro
RLU counts provided a reliable real-time surrogate for
estimating the inactive, bacteriostatic and bactericidal concentra-
tions 6 anti-tuberculosis drugs with differing mechanisms of action
(Figure 2). Importantly, concentrations resulting in $2 log
reductions in RLU by 4–5 days resulted in $2 log reductions in
CFU counts assessed after 8 days of incubation. At these
bactericidal concentrations, drug activity is plainly evident in the
RLU counts measured after as little as 2 days of incubation. Serial
monitoring of the RLU counts also allowed for early detection of
selection of resistant organisms in the case of isoniazid (INH) and
PA-824, consistent with the high frequency of spontaneous
mutations ($10
26) conferring resistance to these two agents
[11,12].
Serial, non-invasive, real-time monitoring of anti-
tuberculosis drug efficacy in vivo
RLU measured in live, anesthetized mice treated with a variety
of anti-tuberculosis drugs effectively discriminated active from
inactive treatments in as little as 2 days (Figure 3A). Treatment
with water or kanamycin (KAN; to which the AlRv strain is
resistant) permitted a nearly 10-fold increase in RLU over the first
3 days, whereas active drugs prevented any increase over baseline.
The most effective agent at reducing RLU counts over the first 3
days, INH, resulted in a 10-fold decrease from baseline. When
RLU counts were normalized to the pre-treatment baseline value
Figure 2. Correlation between RLU and CFU measurements during drug exposure in vitro. Abbreviations: INH, isoniazid; RIF, rifampin; STR,
streptomycin; MXF, moxifloxacin; LZD, linezolid.
doi:10.1371/journal.pone.0029774.g002
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than KAN were significantly more active than water after just 2
days of treatment (p,0.01). Comparison of RLU counts with CFU
counts from lungs and spleens after the same duration of treatment
(Figure 3, B&C) confirms the potential of RLU counts as a
surrogate for CFU counts in screening for anti-tuberculosis
activity. As with the RLU counts, mean spleen CFU counts after
3 days of treatment showed all drugs other than KAN to be
superior to water (p,0.01). On the basis of lung CFU counts,
however, neither PZA nor LZD was statistically superior to water.
These results illustrate the statistical power that may be gained
from serial measurements in the same animal. Interestingly, the
magnitude of the reductions in RLU and CFU did not always
correlate precisely. For example, ethambutol (EMB) and linezolid
(LZD) each reduced the RLU counts by nearly 10-fold over 3 days
(comparable to INH), but had largely bacteriostatic effects on the
basis of lung and spleen CFU counts. On the other hand,
moxifloxacin (MFX) was somewhat less effective at reducing RLU
counts over the first day of treatment, but was the most effective
agent at reducing CFU counts. The reason for such discrepancies
is likely mechanistic in nature, as similar patterns were observed in
vitro for MFX and LZD (Figure 2). For example, protein synthesis
inhibition by LZD may reduce luciferase or substrate synthesis or
FMNH2 availability without cell death whereas inhibition of DNA
gyrase only stops the luciferase reaction upon cell death.
Serial, non-invasive, real-time monitoring of vaccine
efficacy in vivo
Aerosol infection with rBCG30 [13] implanted 2.1160.26 log10
CFU/lung. Four weeks later, the high-dose and low-dose aerosol
infections with AlRv implanted 2.4760.10 and 1.4760.19 log10
CFU/lung, respectively. Serial monitoring of RLU in live,
anesthetized animals revealed a steady increase in RLU counts
in the sham-vaccinated, high-dose-infected group, beginning 2
weeks after infection, peaking 3 weeks after infection, and
remaining elevated above baseline 4 weeks after infection
(Figure 4A). RLU counts in sham-vaccinated mice challenged
with a high dose of M. tuberculosis first exceeded those in rBCG30-
vaccinated mice at 13 days post-challenge (p,0.05) and the
difference became highly statistically significant by 16 days post
challenge (p,0.001). On the other hand, RLU counts among
rBCG30-vaccinated mice which received high-dose, low-dose, and
no AlRv infection could not be differentiated from those in sham-
vaccinated, uninfected mice throughout the 4 weeks post-infection.
The efficacy of rBCG30 vaccination was confirmed by lung CFU
counts at 17 and 27 days after infection, demonstrating that
vaccination restricted M. tuberculosis growth by roughly 1 log10 in
both the high- and low-dose infected mice (p,0.0001). RLU
counts on the lung homogenates themselves correlated very well
with the CFU count results available 4 weeks later (r
2=0.98)
(Figure 4B).
Stability of the autoluminescent M. tuberculosis strains
The AlRv strain was very stable for light production despite
propagation in media without selective kanamycin. After 37 days
of in vitro growth in broth (Figure 1A), 67 (95.7%) of 70 colonies
isolated on drug-free plates retained autoluminescence. Eight
weeks after mouse infection (Figure 1C), 68 (91.9%) of 74 colonies
randomly selected from 3 lungs and 57 (91.9%) of 62 colonies
randomly selected from 3 spleens retained autoluminescence. All
colonies that lost autoluminescence also failed to produce light
after the addition of exogenous substrate (1% decanal in alcohol,
v/v). Finally, 30 of 30 colonies isolated after serial passage of M.
tuberculosis H37Ra integrated with pTYZOK2 in drug-free
medium 3 times over 3 months retained autoluminescence.
Discussion
Although several imaging methods [1,2,3,14,15] have been
developed for quantifying the mycobacterial burden in live
animals, none of them have demonstrated the potential for daily
monitoring using a simple, rapid and inexpensive method feasible
enough to facilitate drug discovery and development efforts in
nearly any laboratory setting. In this study, we demonstrate that a
recombinant autoluminescent strain of M. tuberculosis expressing
luxCDABE enables rapid, serial, non-invasive, real-time monitoring
of the viable bacterial population in live mice during experimental
chemotherapy or in the bacterial challenge phase after vaccina-
Figure 3. Serial, non-invasive, real-time assessment of anti-tuberculosis activity in infected mice. (A) Mean RLU count (6 SD) assessed
daily in live, anesthetized mice and normalized to the baseline RLU value. Mean (B) lung and (C) spleen CFU counts (6 SD) at baseline and after 3 days
of treatment. Abbreviations: KAN, kanamycin; STR, streptomycin; PZA, pyrazinamide; MFX, moxifloxacin; RIF, rifampin; EMB, ethambutol; LZD,
linezolid; INH, isoniazid. Doses (in mg/kg): KAN 150; STR 150; PZA 150; MFX 200; RIF 40; EMB 200; LZD 200; INH 10.
doi:10.1371/journal.pone.0029774.g003
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CFU counts, this advance promises to significantly reduce the
time, effort and resources needed to screen new drug and vaccine
candidates in vivo. By enabling serial imaging of the same animal,
the use of this reporter strain can also reduce the numbers of
animals consumed and improve statistical power. Lower com-
pound requirements, reduced need for BSL-3 animal housing
space, and improved laboratory safety through fewer opportunities
for handling infected tissues and bacterial aerosolization are
additional benefits. There is no need for expensive or biohazard-
ous reagents and the only necessary equipment is a relatively
inexpensive tabletop luminometer. With small sample volumes
(,200 ml) and no exogenous substrate needed, this system is very
amenable to high-throughput screening. For live animal imaging,
it is even possible to avoid the need for anesthesia if the
luminometer is modified to restrain the mouse for the 3-second
detection period. Even the most rapid in vivo assessments based on
prevention of mortality, weight loss, lesion development or
splenomegaly after high-dose challenge with M. tuberculosis require
a minimum of 4 weeks to distinguish active from inactive drugs
and 7–8 weeks for CFU counts to distinguish bactericidal from
bacteriostatic treatments. Under the in vivo testing conditions
evaluated here, 3 days of drug exposure (requiring#10 mg of
compound in vivo) was sufficient to discriminate active drugs from
drug-free controls. The small compound requirement is important
for screening compound libraries, especially for natural products
or other compounds in short supply. Given the rapid, simple
nature of the assay technique, we estimate that up to 500 mice
could be screened per day by one person. Additional studies with
classes of drugs which act by different mechanisms of action will be
required before this system can be considered to be qualified for
routine use.
We did not obtain any autoluminescent M. tuberculosis clones
with an extra-chromosomal plasmid expressing luxCDABE, which
is in agreement with a recent report [1], as well as efforts made 2
decades ago and reported in 1991 [16]. Ironically, the first
integrative vector for mycobacteria was described that same year
[17]. For the time being, it appears to be necessary to use
integrative vectors to generate stable autoluminescent clones. Our
autoluminescent strain of M. tuberculosis was essentially as virulent
as its wild-type parent strain. The integrated luxCDABE operon
was very stable, both in vitro and in vivo (96% and 92% retention of
autoluminescence, respectively). However, it was not completely
stable and the non-luminescent revertants remained so despite the
addition of exogenous substrate, suggesting that the luxCDABE
operon could possibly be excised by the L5 integrase enzyme at a
very low rate [18]. The mutant ratio in the population did not
change very significantly over a long period, providing further
proof that the AlRv strain has a growth rate similar to the WtRv
parent. Like previous authors using luxAB-producing luminescent
strains, we found a strong and consistent correlation between RLU
and CFU counts in actively multiplying bacteria and a reduction
in the RLU/CFU ratio when the organisms entered stationary
phase, presumably due to reduced metabolic activity.
One obvious limitation of the non-invasive method evaluated
here is the large bacillary burden needed for detection. The
autoluminescence of the AlRv strain could not be differentiated
from the background level in live, infected mice when the AlRv
population fell much below 10
6 CFU per lung after aerosol
infection. The greater bacterial burden and more widespread
dissemination of infection following intravenous infection decrease
the lower limit of detection somewhat, although we did not test this
formally. While the modest sensitivity of the test system limits the
ability to detect differences in activity between highly active
compounds or regimens or to evaluate drug effects against smaller
populations of persistent bacilli, a sufficient dynamic range exists
for discriminating active from inactive compounds, bacteriostatic
from bactericidal effects, and weak from strong bactericidal effects.
Although we focused on existing anti-mycobacterial drugs in this
study, the ability to serially image the same animals over time in
this system provides excellent power for discriminating small
effects on bacterial metabolism and viability which should make it
useful for identifying early lead compounds with weaker effects.
Use of immunocompromised mice could further extend the upper
limit of the dynamic range of the assay [6], especially if the RLU/
CFU ratio does not decline as markedly as in immunocompetent
animals after the onset of the adapative immune response, but we
have not examined this possibility.
Assaying autoluminescence in organ homogenates, as opposed
to live mice, also improves the dynamic range of the system, as
Figure 4. Serial, non-invasive, real-time assessment of vaccine efficacy in mice challenged with the AlRv strain of M. tuberculosis. (A)
Mean RLU count (6 S.D.) assessed in live, anesthetized mice vaccinated with either sham (S) or rBCG30 (V) vaccines followed by high-dose (hi), low-
dose (lo) or no aerosol infection with the AlRv strain. (B) Mean CFU and RLU counts (6 SD) from lung homogenates obtained 1, 17 and 27 days after
challenge with the AlRv strain.
doi:10.1371/journal.pone.0029774.g004
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and sensitivity of our system is similar to what has been reported
previously [6].
Enhancing the expression of the luxCDABE operon might
increase the sensitivity of this reporting system. Using a stronger
promoter, a multi-copy vector, a better optimized Shine-Dalgarno
sequence or a codon-optimized luxCDABE operon more suitable
for the high G+C content of mycobacteria [19] may increase the
RLU/CFU ratio. We have compared the hsp60, G13 and MOP
(Mycobacterial Optimized Promoter) promoters in front of luxAB
in Mycobacterium ulcerans, another slow-growing mycobacterium [4]
and found little significant difference among them. Andreu et al
similarly found the hsp60 promoter to drive the highest
luminescence of the 3 luminescent reporters evaluated. A further
effort to augment luciferase production and combine luciferases
with different stability [20] here by adding luxAB from V. harveyi to
plasmids containing luxCDABE did not significantly increase
autoluminescence. Use of a luxCDABE operon codon-optimized
for Streptomyces coelicolor [19], another G+C-rich organism, did not
prove to be very sensitive in mycobacteria [1]. These results
suggest that further increases in luciferase expression may have
limited effects on amount of light produced.
The degree of luminescence may also be improved by
increasing the availability of substrate. In a recent report, cloning
an extra promoter in front of luxCDE to augment synthesis of the
aldehyde substrate increased light output [1]. Complementation
with a gene encoding a NADPH-dependent FMN reductase
increased luminescence by 100-fold in yeast transfected with luxAB
[21]. These may be useful strategies to increase the sensitivity of
our strain as well.
In conclusion, we report the successful engineering of
recombinant autoluminescent strains of M. tuberculosis which retain
full replicative capacity in vitro and in mice. The experiments
described demonstrate the potential use of RLU produced by such
strains as a surrogate marker of bacterial viability in the serial,
real-time evaluation of anti-tuberculosis activity in vitro and in vivo
and of vaccine efficacy in vivo, including non-invasive quantifica-
tion of viable bacteria in mice.
Materials and Methods
Ethics statement
All animal procedures were reviewed and approved by the
Animal Care and Use Committee of Johns Hopkins University.
Each experiment was performed once.
Construction of autoluminescent M. tuberculosis strains
The luxCDABE operon from P. luminescens in pUTmini-Tn5-
luxCDABE –Tc [22] was cut with BamHI+PstI and ligated into
p60LUX [23] cut with the same enzymes to form pTYOEH, an
extra-chromosomal plasmid with a hygromycin resistance marker.
pTYOEH was cut with KpnI and PstI and the fragment containing
luxCDABE under the Hsp60 promoter [10] was inserted into
pMH94 [17] cut with the same enzymes to give pluxOK. The
attP:Int cassette in the plasmid pblueint was inserted into pluxOK
cut with KpnI and ScaI-HF
TM to give pTYOK. pTYOEH was also
cut with KpnI and inserted into pMH94 and pTY60K [4] KpnI sites
to give pTYZOK1 and pTYZOK2, and pOAIK1 and pOAIK2,
respectively (the only difference between plasmid1 and plasmid2 is
the orientation of the fragment inserted). In pTYZOK, there is
one copy of luxAB from Vibrio harveyi and one copy of luxCDABE
from P. luminescens, each under one Hsp60 promoter. In pOAIK1/
pOAIK2, there is an additional copy of luxB from V. harveyi
downstream of luxCDABE. In the end, one extra-chromosomal
plasmid (pTYOEH) and three types of integrative plasmids
(pTYOK, pTYZOK1/pTYZOK2 and pOAIK1/pOAIK2) were
created and transformed into M. tuberculosis H37Rv and H37Ra by
electroporation as described previously [4]. Several colonies from
each plasmid/strain combination were picked from KAN-
containing plates, homogenized in 2ml 7H9 broth with 0.05%
Tween80, and incubated at 37uC, with shaking. When the
OD600 nm reached 0.5, luminescence was detected using a 20/20
n
luminometer (Turner BioSystems), measuring light production
over 3 sec. Strains were compared on the basis of RLU per ml of
culture and the RLU/CFU ratio.
In vitro growth curves of AlRv and WtRv
Autoluminescent M. tuberculosis H37Rv transformed with
pTYOK (AlRv) was passaged once in BALB/c mice (Charles
River, Germantown, MD) by intravenous injection. Autolumines-
cent colonies isolated on KAN-containing plates were homoge-
nized with sterile glass beads in a 250 ml flask containing 30 ml
7H9 with Tween80. A culture of the parent H37Rv strain (WtRv)
was started simultaneously. When the cultures reached an
OD600 nm of 0.6, the culture was diluted 150-fold in 30 ml of
fresh 7H9 with Tween80 and incubated at 37uC, with shaking. At
prescribed time points, 100 ml aliquots were assayed in triplicate
for RLU counts and plated in serial 10-fold dilutions for CFU
counts. CFU counts were determined after 4 weeks of incubation.
In vivo growth curves of AlRv and WtRv and time-to-
death curves of mice infected with these 2 strains
After mouse passage as described as above, 10 ml of undiluted
broth culture and 10 ml of a 100-fold diluted culture were used to
infect 95 4-to-6-week-old female BALB/c mice by aerosol
infection using the Inhalation Exposure System (Glas-Col, Terre
Haute, IN). Three mice per group were killed the day after
infection and weekly thereafter for 8 weeks. The mice were first
anesthetized by isoflurane inhalation and the RLU count was
determined by laying the breast of the mouse over the detection
hole of the luminometer and measuring light production for 3 sec
for 3 times (Figure S1). The mice were then euthanized. The lungs
and spleens were removed aseptically, washed in 14 ml PBS, and
homogenized in 2 ml PBS (lungs) or 1 ml PBS (spleens). A 0.5 ml
aliquot of homogenate was used for RLU detection. The
remaining 0.5 ml of was serially diluted and plated on Mid-
dlebrook 7H11 agar. CFU counts were determined after 4 weeks
incubation in 37uC. Eight additional mice in the high-dose group
for each strain were held to determine time-to-death. The mice
were euthanized as soon as they appeared moribund.
Serial, real-time monitoring of anti-tuberculosis drug
activity in vitro
The activity INH, RIF, STR, MFX, LZD, and PA-824 was
assessed over a range of 4-fold increasing concentrations prepared
in 1 ml of 7H9 broth to which 0.2 ml of a 1/100 dilution of AlRv
broth culture (OD600 nm ,0.8) grown in 7H9 broth +0.05%
Tween80 was added. RLU counts were determined daily, in
triplicate, for 8–14 days. After 0 and 8 days (and after 14 days for
INH and PA-824), 0.5 ml aliquots of serial 10-fold dilutions were
plated on 7H11 and incubated at 37uC for up to 28 days.
Serial, non-invasive, real-time monitoring of anti-
tuberculosis drug activity in vivo
A log-phase culture of AlRv adjusted to an OD600 nm of 0.1 was
used to infect 5-to-6-week-old female BALB/c mice by tail vein
injection. The day after infection (day 0), RLU counts were
Autoluminescent M. tuberculosis Infection in Mice
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described above. Forty mice with similar RLU readings were
randomly allocated to treatment groups (4 mice/group) and
individually marked. The treatment groups received: water alone
(negative control), KAN (150 mg/kg) (a second negative control),
INH (10 mg/kg), RIF (40 mg/kg), PZA (150 mg/kg), EMB
(200 mg/kg), STR (150 mg/kg), MFX (200 mg/kg), or LZD
(200 mg/kg). STR and KAN were administered by subcutaneous
injection in 0.2 ml sterile PBS. The remaining drugs were
prepared and administered by gavage in 0.2 ml as previously
described [24,25,26,27]. Treatment was administered on days 0, 1
and 2. RLU were detected under anesthesia daily. Mice were
killed on day 0 and day 3 after to determine lung and spleen CFU
counts as described above.
Rapid, serial, non-invasive, real-time monitoring of
vaccine efficacy in mice challenged with M. tuberculosis
5-to-6 week-old female BALB/c mice were vaccinated by the
aerosol route with either (i) a broth culture (OD600 nm of 0.25) of a
recombinant BCG strain over-expressing antigen 85B (rBCG30 or
V), or (ii) 7H9 broth only (Sham or S), using the Inhalation
Exposure System. The day after vaccination, 4 mice from the
former group were killed to determine the number of rBCG30
implanted. Four weeks later, 12 mice from each vaccination group
were aerosol-infected with a 50-fold dilution (hi) of a broth culture
of the AlRv strain (original OD600 nm of 0.6). Another 12 mice
from each group were infected with a 500-fold dilution (lo) of the
original culture. Additional mice were vaccinated but not
challenged with AlRv (no). The day after infection with AlRv, 4
mice from each of these groups were killed and the lung
homogenates were plated on 7H11 plates containing KAN at
25 mg/ml (to select for AlRv) and plates containing hygromycin at
40 mg/ml (to select for rBCG30) for CFU count determination.
RLU counts were determined under anesthesia on days 1, 6, 10,
13, 15, 17, 20, 22, 24 and 27 after AlRv infection. Four mice in V-
hi and S-hi groups were killed for RLU and CFU counts from lung
homogenates at day 17 (the second consecutive time point at
which the live RLU counts were significantly different (P,0.05 by
t test)). All remaining AlRv-infected mice were killed for RLU and
CFU counts from lung homogenates at day 27.
Statistical analysis
Group means were compared using t tests or one-way ANOVA
with Dunnett’s post-test, controlling for multiple comparisons in
each case. Prism 5 (GraphPad Software, San Diego, CA) was used
for all analyses.
Supporting Information
Figure S1 Detection of RLU from live mice using the
Turner BioSystems 20/20
n luminometer. (A) An anesthe-
tized mouse is placed in prone position onto reader with limbs
spread out to ensure maximum exposure to chest area. (B) The
unit is closed and covered with black cloak to prevent any outside
light contamination.
(TIF)
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